Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3% – Should You Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded down 3% during mid-day trading on Tuesday . The stock traded as low as $11.80 and last traded at $11.84. 40,221 shares traded hands during mid-day trading, a decline of 46% from the average session volume of 74,921 shares. The stock had previously closed at $12.20.

Gyre Therapeutics Stock Down 2.5 %

The business’s 50 day simple moving average is $12.83 and its 200-day simple moving average is $12.62.

Institutional Trading of Gyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC bought a new stake in Gyre Therapeutics in the third quarter valued at approximately $47,000. Barclays PLC increased its holdings in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. State Street Corp grew its position in Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares in the last quarter. Rhumbline Advisers acquired a new position in Gyre Therapeutics in the 2nd quarter valued at $123,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at $166,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.